MyHep LVIR™ (28 tabs) is a licensed generic of Harvoni® (Sofosbuvir/Ledipasvir) produced in an FDA approved factory in India. It’s a direct-acting antiviral prescription medication for the treatment of chronic Hepatitis C genotype 1, 4, 5 or 6 in patients with or without liver cirrhosis (compensated), it’s not suitable for genotypes 2 or 3. So if patients did not get tested for genotype, they should be treated with Epclusa® instead of Harvoni®. For the majority of patients, 12 weeks (3 bottles) of treatment is needed to reach cure. But for treatment experienced patients or for those with advanced Liver cirrhosis (decompensated), treatment duration is 24 weeks (6 bottles). Harvoni® is approved by the FDA and EMA for use in adults and children aged 3 years and older.
- Harvoni® overall established cure rate in genotype 1, 4, 5 or 6 patients is roughly 92%
- Harvoni® side effects profile is quite mild especially with enough water intake
- Consult a doctor before concurrent administration of other drugs and supplements
Active Ingredients : Sofosbuvir 400 mg / Ledipasvir 90 mg
Produced by Mylan Pharmaceuticals® of the United States (US FDA approved manufacturer)